ライフサイエンスコーパス: antiviral activity

1 tivity of Gag is a major requirement for the antiviral activity.

2 benzyl boronic acid was essential for potent antiviral activity.

3 en neutralizing antibodies or compounds with antiviral activity.

4 CD8+ T cells are recruited to the liver for antiviral activity.

5 AM580, which accounts for its broad-spectrum antiviral activity.

6 inhibition activity and/or FcgammaR-mediated antiviral activity.

7 ith the treatment appear to be important for antiviral activity.

8 that protein degradation contributes to its antiviral activity.

9 ation by host RNAs, a potential trade-off to antiviral activity.

10 -like domain and NYN endonuclease domain for antiviral activity.

11 that two isoforms of TRIM7 have differential antiviral activity.

12 t quantitatively correlate with the level of antiviral activity.

13 ied have not been previously associated with antiviral activity.

14 ted genes (ISGs) previously reported to have antiviral activity.

15 protective properties like an extracellular antiviral activity.

16 f IFN-stimulated genes (ISGs), which mediate antiviral activity.

17 gle-stranded (ss)DNA cytosine deaminase with antiviral activity.

18 or adaptive immunity nor associated with any antiviral activity.

19 get RNA nucleotide content influence Cas13's antiviral activity.

20 el small CCR5 inhibitors and evaluated their antiviral activity.

21 uire FcgammaR engagement for optimal in vivo antiviral activity.

22 ular localization of the protein and reduced antiviral activity.

23 as potent viral DNA mutators and have broad antiviral activity.

24 erpinning this unusual enzyme's wide-ranging antiviral activity.

25 ing affinity with a concomitant reduction in antiviral activity.

26 and colon is required for enteric IFN-lambda antiviral activity.

27 at the same time, positively regulating its antiviral activity.

28 petitively inhibit ssDNA deaminase-dependent antiviral activity.

29 a review of variables that are critical for antiviral activity.

30 s of life also elicit a unique RNA-targeting antiviral activity.

31 ization, packaging into HIV-1 particles, and antiviral activity.

32 nced pharmacological profiles and heightened antiviral activity.

33 nhibition of JAK activity contributes to its antiviral activity.

34 ssemble into viral particles and had reduced antiviral activity.

35 tion and promoted SAMHD1 dNTPase-independent antiviral activity.

36 T592 phosphorylation and deactivation of its antiviral activity.

37 improved RNase H inhibition and significant antiviral activity.

38 d ZMPSTE24 expression is necessary for IFITM antiviral activity.

39 of these mannosidases are required for this antiviral activity.

40 f RNase H inhibition as well as the observed antiviral activity.

41 sertion into viperin and hence for viperin's antiviral activity.

42 f literature suggesting ivermectin has broad antiviral activity.

43 iochemical inhibition largely correlated the antiviral activity.

44 ne reduced basal ISG expression and improved antiviral activity.

45 SAR) for identifying RNase H inhibitors with antiviral activity.

46 llowing viral infection and exhibited potent antiviral activity.

47 synthetase (OAS)-RNase L pathway is a potent antiviral activity.

48 exploits radical SAM chemistry to exert its antiviral activity.

49 al activity is a correlate of broad-spectrum antiviral activity.

50 TRIM32 is an E3 ubiquitin ligase with innate antiviral activity.

51 es another important aspect of the protein's antiviral activity.

52 er functions, including immunoregulation and antiviral activity.

53 some of which showed moderate cytotoxic and antiviral activity.

54 c molecule was generated with three distinct antiviral activities.

55 e many nucleic acid species for a variety of antiviral activities.

56 nd investigated its isoforms' expression and antiviral activities.

57 creted factors that are well-known for their antiviral activities.

58 is a nucleotide analogue prodrug with broad antiviral activity(1,2) that is currently being investig

59 n indicated that the compounds exerted their antiviral activities after the entry process, likely at

60 Furthermore, these immune sera showed antiviral activities against a panel of genetically dist

61 responsible for their demonstrated in vitro antiviral activities against COVID-19.

62 However, their antiviral activities against currently circulating influ

63 tigational compound with a broad spectrum of antiviral activities against RNA viruses, including seve

64 cellular H2S is associated with significant antiviral activity against a broad range of emerging env

65 pyrazine analog that has demonstrated potent antiviral activity against a broad spectrum of viruses i

66 tants quantitatively predict their selective antiviral activity against a CG-enriched HIV-1 strain.

67 nents of the innate immune response, exhibit antiviral activity against a multitude of viruses includ

68 ectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA virus

69 equence in domestic chicken and describe its antiviral activity against a prototypical avian retrovir

70 IV) agents, while being completely devoid of antiviral activity against a wide range of DNA viruses.

71 e reported that HO-1 can exert a significant antiviral activity against a wide variety of viruses, in

72 Consequently, CLR01 and CLR05 display broad antiviral activity against all enveloped viruses tested,

73 In vitro, these antimicrobials had expressed antiviral activity against all five viruses through all

74 thieno[3,2-b]pyrrole 1b that displayed good antiviral activity against CHIKV infection in vitro.

75 In infected cells, antiviral activity against Dengue virus serotype 2 using

76 in an interferon-dependent manner, displays antiviral activity against DENV, and localizes to the DE

77 racterize an interferon-stimulated gene with antiviral activity against DENV, as well as to propose a

78 UV-4B has broad-spectrum antiviral activity against diverse viruses including den

79 ggesting that the Toll pathway has conserved antiviral activity against DNA nudiviruses, which have e

80 ex (MHC) class II transactivator (CIITA) has antiviral activity against EBOV.

81 ulate lung inflammation but it has no direct antiviral activity against ECTV.

82 t with membrane interfaces might exert broad antiviral activity against enveloped viruses.

83 We found that IFN-alpha and IFN-lambda1 antiviral activity against HCV was impaired in IL28B T/T

84 l of cancer and leukemia cell lines and some antiviral activity against HCV.

85 pegylated IFN-alpha (peg-IFN-alpha)-induced antiviral activity against hepatitis C virus (HCV) repli

86 These compounds showed antiviral activity against hepatitis C virus.

87 Sofosbuvir has shown antiviral activity against HEV in vitro but clinical uti

88 Sofosbuvir may have some antiviral activity against HEV when added to ribavirin.

89 vel analogue, NBD-14189 (Ref1), which showed antiviral activity against HIV-1(HXB2), with a half maxi

90 We show that PG naturally exerts antiviral activity against HSV-1 and HSV-2 infections.

91 ly used disaccharide trehalose, which showed antiviral activity against Human Cytomegalovirus (HCMV)

92 upted IFITM3 oligomerization and reduced its antiviral activity against Influenza A virus.

93 uated 10 previously described compounds with antiviral activity against mammarenaviruses for their ab

94 on-sulfur (Fe/S) cluster is critical for its antiviral activity against many different viruses.

95 RNA production and displayed broad-spectrum antiviral activity against other alphaviruses and CHIKV

96 RDV shows broad-spectrum antiviral activity against RNA viruses, and previous stu

97 s resistance protein A (MxA), which displays antiviral activity against several RNA and DNA viruses,

98 GSK3532795 demonstrated potent antiviral activity against subtype B (monotherapy or wit

99 exposures for each agent that will maximize antiviral activity against susceptible and drug-resistan

100 Investigations of antiviral activity against the human respiratory syncyti

101 very of a small molecule, ML336, with potent antiviral activity against VEEV.

102 compound II), low cytotoxicity, and enhanced antiviral activity against wild-type (WT) HIV-1 RT and r

103 the highest affinity for sfRNA and displayed antiviral activity against ZIKV in Ae. aegypti cells.

104 ecificities of antibodies that mediate these antiviral activities and provide insights into the relat

105 ing the antiviral defense by inducing direct antiviral activities and shaping the adaptive immune res

106 However, the antiviral activities and the underlying mechanisms of HB

107 ar DNA damage response pathways that possess antiviral activities and utilize DNA damage response pat

108 osis.IMPORTANCE The mechanisms of tetherin's antiviral activities and viral tetherin antagonism have

109 egrase strand transfer inhibitor with potent antiviral activity and a long half-life when administere

110 ron (IFN)-inducible GTPases that exert broad antiviral activity and are important mediators of host d

111 ulator in innate immune responses due to its antiviral activity and association with autoimmune disea

112 e protection by activating FcgammaR-mediated antiviral activity and can drive antigenic drift at the

113 Their antiviral activity and channel blocking ability were det

114 n structure of HBV RNA was important for its antiviral activity and cleaved by MCPIP1 in the cell-fre

115 ype A3H-RNA interaction is essential for A3H antiviral activity and for two deaminase-independent pro

116 nto an antibody combination that potentiates antiviral activity and is able to prevent EVD in nonhuma

117 ur results further extend ivermectin's broad antiviral activity and provide a mechanistic underpinnin

118 These data indicate that DHX9 possesses antiviral activity and that SM may suppress the antivira

119 already approved for human use that may have antiviral activity and therefore could potentially be ra

120 ytes with a broad-spectrum antibacterial and antiviral activity, and a low rate of inducing bacterial

121 omatic hypermutations are required for broad antiviral activity, and germline-approximating variants

122 ymphopoietin (TSLP), in airway inflammation, antiviral activity, and lung function.

123 a membrane localization is required for Ser5 antiviral activity, and Ser5-001 is the predominant isof

124 er of CpGs does not predict the magnitude of antiviral activity, and that CpGs can inhibit HIV-1 gene

125 IRF3 activation, interferon production, and antiviral activity are compromised in cell cultures and

126 cquires its radical SAM Fe/S cluster to gain antiviral activity are poorly understood.

127 GS-6207 exhibits antiviral activity at picomolar concentrations against a

128 Thus, caution must be taken when predicting antiviral activity based on percent channel blockage in

129 boosted luminal NETosis and halted cytolytic antiviral activities but did not affect the T(H)2 respon

130 rferon-stimulated gene with well-established antiviral activity but limited mechanistic understanding

131 ntiviral nucleosides that demonstrate potent antiviral activity but poor bioavailability.

132 trials suggest that such antibodies can have antiviral activity but, as with small-molecule antiretro

133 to further explore a potential intracellular antiviral activity by eosinophils.

134 ance phenotype in vivo Activation of RNase L antiviral activity by flavivirus infection was indicated

135 This study proposes that ZIKV evades RNase L antiviral activity by generating a viral genome reservoi

136 Here, we delineate a novel mechanism of antiviral activity by studying the activity of tweezer v

137 Besides its antiviral activity, chloroquine might also mitigate the

138 The antiviral activity coincided with the decrease of viral-

139 NBD-14107, showed significant improvement in antiviral activity compared to the lead entry antagonist

140 s, HLA-C-licensed NK cells displayed reduced antiviral activity compared to their unlicensed counterp

141 tripartite motif [TRIM] protein with innate antiviral activity) contributes to a T helper type 2 bia

142 an differ significantly, overall, tetherin's antiviral activity correlates with physical tethering of

143 Molecular docking of analogues that retained antiviral activity demonstrated a relationship between p

144 f convallotoxin, although having more potent antiviral activity, did not show an improved selectivity

145 a natural product with known anticancer and antiviral activity, dramatically affects alpha-synuclein

146 osomes containing a decoy receptor show weak antiviral activity due to the lack of membrane disruptio

147 utant was used to identify AGO proteins with antiviral activities during infection.

148 A3H antiviral activity encompasses multiple molecular functi

149 identified two BA derivatives with improved antiviral activity for further mechanistic studies.

150 Fc-mediated antiviral activity has been implicated as a secondary co

151 Host proteins with antiviral activity have evolved as first-line defenses t

152 tes are known to promote Ag presentation and antiviral activities; however, the impact of aging on mo

153 IAV replication; however, to counteract host antiviral activities, IAVs have developed different inhi

154 ht into the mechanism of IFN-lambda-mediated antiviral activity.IMPORTANCE Human noroviruses (HNoVs)

155 f the CpG in the viral genome determines its antiviral activity.IMPORTANCE Some RNA virus genomes are

156 The inhibitor exhibited significant antiviral activities in cells (EC(68): 300-600 nM) and i

157 SV-infected microglia confer STING-dependent antiviral activities in neurons and prime type I IFN pro

158 type I IFN (IFNalpha/beta) have overlapping antiviral activities in the lung.

159 11 elicited increased anti-proliferative and antiviral activities in vitro and in vivo.

160 60 new analogues and determination of their antiviral activity in a single-cycle and a multicycle in

161 Defensins have direct antiviral activity in cell culture, with varied mechanis

162 compounds (ebselen) also exhibited promising antiviral activity in cell-based assays.

163 regimen, was evaluated for distribution and antiviral activity in cerebrospinal fluid (CSF) as well

164 regimen, was evaluated for distribution and antiviral activity in cerebrospinal fluid (CSF) as well

165 rrant Matrine to be further explored for its antiviral activity in clinical settings.

166 Strikingly, antiviral activity in infected chicken cells, accompanie

167 s spectrometry, protein crystallography, and antiviral activity in infected human T-cell assays.

168 These compounds also showed potent antiviral activity in neuronal cells, such as A172 and S

169 e-dependent pharmacokinetics, and had potent antiviral activity in patients with CHB.

170 1 receptor (IFNAR) was essential for acetate antiviral activity in pulmonary epithelial cell lines an

171 g since it is also involved in activation of antiviral activity in the absence of STAT1.

172 Drugs with demonstrated antiviral activity in the nonhuman primate models alread

173 The downregulation of antiviral activity in the presence of a functional proin

174 ly active mouse MX1 variant that only exerts antiviral activity in the presence of a small molecule d

175 not the N-terminal mutant, maintained potent antiviral activity in the presence of Vif.

176 functions accounted for 25-45% of the total antiviral activity in these separate experiments.

177 truct that recapitulates VX-787's biological antiviral activity in vitro.

178 HPV16) infection in vitro and maintain their antiviral activity in vivo, while the glycooligomers exe

179 nd with potent AM2-S31N channel blockage and antiviral activity, in this study we report an expeditio

180 oup, I determined that an interferon-induced antiviral activity inhibited the release of enveloped vi

181 ets of pharmacological agents that displayed antiviral activity: inhibitors of mRNA translation and p

182 ith substituted imidazoles on improvement of antiviral activity is disclosed.

183 chinery for generating IFN responses and its antiviral activity is intact in these cells: treatment o

184 The mechanism of antiviral activity is through inhibition of viral RNA pr

185 2 mutant constructs, we demonstrate that its antiviral activity is uniquely independent of the RING d

186 Despite the antiviral activity known for PKR against many other viru

187 at Fc function can contribute to the overall antiviral activity, making them distinct from standard A

188 ons of the genome sensitize the virus to ZAP antiviral activity more efficiently than insertions into

189 To overcome this antiviral activity, most lentiviruses express a viral ac

190 In this study, we evaluated the in vitro antiviral activities of GRFT and its synthetic trimeric

191 Here we report the antiviral activities of GS-5734 and the parent nucleosid

192 ry role that this domain may play in the two antiviral activities of IFITM3.IMPORTANCE IFITM proteins

193 -2-mNG was successfully used to evaluate the antiviral activities of interferon (IFN).

194 These data suggest that the antiviral activities of noncanonical PARP isozyme activi

195 The antiviral activities of synthesized Kalpha2-helix peptid

196 The focus of this review is the antiviral activities of the IFN/ISG system.

197 x1 genes that might explain species-specific antiviral activities of these proteins.

198 These findings provide evidence that the antiviral activities of type I IFN production and apopto

199 In this study, we assessed the influenza antiviral activity of 10 compounds previously shown to i

200 Here, we present data assessing the antiviral activity of 20 FDA-approved drugs against SARS

201 Here, we present data on the antiviral activity of 20 FDA-approved drugs against SARS

202 Here, we demonstrate the potent antiviral activity of a broad-spectrum ribonucleoside an

203 We investigated the antiviral activity of a defined Spirulina platensis micr

204 Taken together the data characterize the antiviral activity of a novel HCMV inhibitor that drives

205 We exploit the uniquely broad spectrum antiviral activity of a parainfluenza F-derived peptide

206 d H5N1 virus replication and compromised the antiviral activity of A77 1726.

207 o evaluate the pharmacokinetics, safety, and antiviral activity of ABI-H0731, an investigational inhi

208 The potential antiviral activity of AdrA was addressed in hepatitis B

209 hus, although STING is indispensable for the antiviral activity of AdrA, type I IFN and TNF-alpha are

210 ion versus effector functions to the overall antiviral activity of an antibody remains unknown.

211 vo study of HIV-1 Env-receptor interactions, antiviral activity of antibodies and humoral responses a

212 The antiviral activity of antibodies reflects the bifunction

213 importance of these interactions in driving antiviral activity of APOBEC3H.

214 gagement does not always improve the in vivo antiviral activity of BnAbs.

215 Notably, the antiviral activity of both ALA1 and ALA2 was abolished b

216 protective role for capsid and suggest that antiviral activity of capsid- and protease-targeting ant

217 These insights into the mechanism of antiviral activity of CD4mc should assist efforts to opt

218 We also find that antiviral activity of CD8(+) T cells within the brain ma

219 silico, offer an explanation for the lack of antiviral activity of compounds active in the TEV assay,

220 nanostructure provides another dimension for antiviral activity of decoy molecules.

221 of DHX30, denoted DHX30N, possesses all the antiviral activity of DHX30 and contains a dsRNA-binding

222 Here we describe the antiviral activity of diarylamines derived from anthrani

223 uctural insights into the multimodal, potent antiviral activity of GS-6207 and provide a means for ra

224 The post-infection antiviral activity of h5B3.1 was evaluated in vivo by ad

225 udies show that the predominant mechanism of antiviral activity of HIV NAbs is through inhibition of

226 The key function of Vif is to disrupt the antiviral activity of host APOBEC3 (apolipoprotein B mRN

227 omain-containing protein 1) is known for its antiviral activity of hydrolysing deoxynucleotides requi

228 dels have been extensively used to study the antiviral activity of IFIT (interferon-induced protein w

229 in vivo In this study, we characterized the antiviral activity of Ifitm3 against West Nile virus (WN

230 preseroconversion are more sensitive to the antiviral activity of IFITMs than variants from patients

231 ied gene products that are important for the antiviral activity of interferon against vesicular stoma

232 While the antiviral activity of interferon has long been known, th

233 ask whether resistance was due to the direct antiviral activity of ISGs or whether cells were nonperm

234 Despite this promise, the antiviral activity of ivermectin has not been consistent

235 evaluated the safety, pharmacokinetics, and antiviral activity of multiple doses of JNJ-6379 in pati

236 These results confirm the robust antiviral activity of N6-LS in vivo, supporting the furt

237 We evaluated the in vivo antiviral activity of N6-LS, alone or in combination wit

238 es revealed that IFITMs markedly enhance the antiviral activity of nAbs and suggest a cooperative eff

239 In this study, we examined the antiviral activity of natural compounds against the foll

240 The antiviral activity of nucleoside reverse transcriptase i

241 ich offer the most informative assessment of antiviral activity of patient sera against viral infecti

242 JUNV's ability to antagonize the antiviral activity of PKR appears to be complete, as sil

243 mentary in inhibiting HIV-1 replication, the antiviral activity of SAMHD1 in our primary cell model a

244 says to rapidly and conveniently measure the antiviral activity of SARS-CoV-2-specific antibodies.

245 eutralizing antibodies, directly linking the antiviral activity of SERINC5 with remodeling of the HIV

246 The antiviral activity of TDRD7 depended on its ability to i

247 esistance selection, we show that the potent antiviral activity of telaprevir was due to 2A(pro) inhi

248 NHR trimer have been adopted to increase the antiviral activity of the CHR peptides.

249 The antiviral activity of the eight identified compounds aga

250 irming that resistance was due to the direct antiviral activity of the IFN response.

251 In antiviral assays, the excellent antiviral activity of the prodrugs that was found in CEM

252 thogenic viruses, we observed broad-spectrum antiviral activity of these compounds beyond our initial

253 The antiviral activity of these compounds in an Ebola pseudo

254 We further sought to correlate the antiviral activity of these peptides and their effects o

255 Antiviral activity of this purified microbial molecule a

256 -1 accessory protein Nef can antagonize this antiviral activity of TIM-1 while host restriction facto

257 evaluating the safety, pharmacokinetics, and antiviral activity of UB-421 monotherapy in HIV-infected

258 ane-binding elements of MA contribute to the antiviral activity of uncleaved MA-CA protein.

259 In an ex vivo challenge assay, the antiviral activity of VCV and/or MK-2048 was not correla

260 Here, we present a comparative view of the antiviral activity of virus-derived small interfering RN

261 ect profile, pharmacokinetic properties, and antiviral activity of VRC01 in persons with HIV infectio

262 oss-species activities, rmIFN exhibited high antiviral activity on human cells, suppressing HIV repli

263 This review focuses on the mode of action, antiviral activity, pharmacokinetics, clinical indicatio

264 d RNA was detected by OAS3 to induce RNase L antiviral activity prior to ZIKV infection, we observed

265 Potent antiviral activity profiles were obtained depending on t

266 Among them, eight drugs showed antiviral activities, providing a new battery of drugs t

267 has been found to be induced by IFN, but its antiviral activity remains elusive.

268 Antiviral activity, safety, and pharmacokinetics of pimo

269 via a structure-based approach and performed antiviral activity screening to identify compounds 29 an

270 t monotherapy studies to evaluate safety and antiviral activity should be conducted prior to proceedi

271 r TRIM69 multimerization is required for its antiviral activity, suggesting that TRIM69 functions by

272 narily conserved splice variant shows higher antiviral activity than full-length Md1, but reduced pro

273 urine Ser1, Ser2, and Ser3 exhibit very poor antiviral activity, they are also targeted by glycoMA fo

274 le that WDB002 or an analog may exert useful antiviral activity through its ability to form high-affi

275 porcine hemoglobin subunit beta (HB) exerts antiviral activity through regulation of type I interfer

276 the first assessment of carbon dots' (CDots) antiviral activity to human norovirus virus-like-particl

277 that remdesivir (RDV) and IFNb have superior antiviral activity to LPV and RTV in vitro.

278 Translation of in vitro antiviral activity to the in vivo setting is crucial to

279 dosing regimen based on a comparison of the antiviral activity, tolerability, and safety of the two

280 ntermediate filaments, and such cells showed antiviral activity toward VSV.

281 t not those with only nuclear bodies, showed antiviral activity toward VSV.

282 ration of AL-794, significant dose-dependent antiviral activity was noted, with a greater decrease in

283 Target exposures were reached and antiviral activity was observed.

284 to determine the molecular mechanisms of its antiviral activity, we show that PG specifically inhibit

285 ecurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested,

286 disrupt membrane integrity but with no known antiviral activity, were tested for the ability to inhib

287 r enzymes, ZDHHC20 uniquely increased IFITM3 antiviral activity when both proteins were overexpressed

288 f HLA-C expression demonstrated by increased antiviral activity when exposed to viral strains with di

289 maller than 10(-6) while they do not exhibit antiviral activity when kd is 10(-5) or higher although

290 /M2 channels, and (ii) the compounds display antiviral activity when they have kd equal or smaller th

291 Some ISGs have specific antiviral activity, whereas others regulate the cellular

292 Thus, NORE1A has antiviral activity, which is specifically antagonized by

293 Antiviral activity, which is stimulated by minute amount

294 hibitor (NRTI) designed to maintain in-vitro antiviral activity while minimising off-target effects.

295 yophyllene, linalool, and eucalyptol possess antiviral activity, while (ii) thujones do not, and (iii

296 Combining this antiviral activity with Cas13-based diagnostics, we deve

297 inical candidate by establishing synergistic antiviral activity with existing HIV-1 drugs and clinica

298 (total 120 mannoses)-exhibit an outstanding antiviral activity with IC50 in the sub-nanomolar range!

299 tional studies allowed to correlate the best antiviral activity with the ( R) absolute configuration

300 RNA is essential for virion infiltration and antiviral activity, yet the mechanisms of viral RNA reco